What would happen if instead of a personalized treatment plan your doctor used a one-size-fits-all standard of care?
A recent government proposal to change Medicare Part B could create barriers to personalized care. This case study looks at personalized treatment vs. one-size-fits-all standards. For a patient like Joyce, diagnosed with stage IV metastatic breast cancer, HER2 negative and managing other health conditions, the specific course of treatment has real implications.
Keeping treatment decisions between patients and their physicians is important to ensure care is personalized for an individual, yielding the best result for the patient and the health care system at large. Misuse of standardized, one-size-fits-all treatment protocols can impede individual doctor-patient decision-making and lead to serious health consequences for patients.
Download Joyce's profile as a PDF here.
Learn more at PhRMA.org/PartB.
Allyson Funk Ally is a former senior director of public affairs at PhRMA focused on advocacy issues for the biopharmaceutical industry. Her expertise includes Medicare, Medicaid, 340B, health reform and more. Prior to PhRMA, her experience included leading health communications for a large membership organization, supporting public affairs clients and working for the governor of Louisiana.